Aureus Pharma extends collaboration with Sanofi-Aventis
Aureus Pharma, a provider of knowledge management solutions to aid discovery in the life sciences industry, announced that sanofi-aventis has become its first customer for the company's recently released AurSCOPE® Ion Channel database. This agreement extends the collaboration between Aureus Pharma and sanofi-aventis which already covered other Aureus databases. The financial terms of the agreement were not disclosed.
This new database gives researchers access to information on all major ion channels already described in scientific literature, allowing the identification, validation and prioritization of new targets and ligands for drug discovery. Sanofi-aventis plans to use the AurSCOPE-Ion Channel database to help researchers speed up its discovery process in a number of fields.
The agreement means that Aureus Pharma is successfully expanding its range of knowledge management tools, and increasing market penetration. The company already has collaboration agreements with other life science companies including Roche.
The market importance of ion channels as a class of targets for drug discovery is growing. They play a crucial role in all functions in the human body and are targets in a wide variety of diseases including cystic fibrosis, epilepsy and arrhythmia. They remain one of the less exploited therapeutic target areas studied today, one of the reasons why Aureus Pharma has developed its AurSCOPE to accelerate research in this field.
The sanofi-aventis Central Anti-Counterfeit Laboratory was officially inaugurated at the Tours pharmaceutical plant (in the Department of Indre-et-Loire, France) by Hervé Novelli, Minister of State to the Minister for the Economy, Industry and Employment with responsibility for Business, Tr ... more
ThalesNano Inc. and sanofi-aventis R&D announced the signing of a research and development collaboration agreement focusing on continuous process chemistry technologies.The collaboration will focus on the development and implementation of continuous process technologies from research to ful ... more
Sanofi-aventis enters the Dow Jones Sustainability World Indexes (DJSI World), the leading global
index tracking the financial performance of the leading sustainability-driven companies worldwide.
The DJSI World covers the top 10% of the biggest 2,500 companies in the Dow Jones World Index ... more
Aureus Pharma announced changes in Aureus´s Executive and Supervisory Boards. Jason Theodosiou has been appointed Chief Executive Officer (CEO). Theodosiou will replace André Michel, founder of Aureus who has been appointed to Chairman of the Supervisory Board. These changes will become eff ... more
Aureus Pharma and ChemAxon announced that they have been awarded a European Eureka project along with pharmaceutical partner sanofi-aventis and academic partner Budapest University of Technology and Economics. The goal of the project KnowTox® is to build a new knowledge base related to hepa ... more
Aureus Pharma announced that GlaxoSmithKline (GSK) has signed a multi-year license for Aureus Pharma's AurSCOPE Knowledge databases. Researchers at GSK's global research and development centers will gain access to Aureus' Knowledge databases including AurSCOPE GPCR, Ion Channel, hERG, and A ... more